Insilico Medicine (“Insilico” HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to use its proprietary end-to-end platform, Pharma.AI, to advance drug candidates across the company’s therapeutic areas. 

The collaboration is designed to identify clinically differentiated drug candidates for promising therapeutic targets. Using advanced generative models from the earliest stages of design, the teams aim to improve the quality of candidate molecules and optimize them to achieve best-in-class efficacy and safety criteria.

A new retrospective cohort study conducted at the University Medical Center Hamburg-Eppendorf has revealed that hypoxic liver injury (HLI) is a frequent and highly consequential complication among critically ill patients suffering from acute respiratory distress syndrome (ARDS). The findings highlight HLI as a significant prognostic marker associated with markedly increased mortality in this vulnerable population. 

A Norwegian Swedish clinical trial published in the New England Journal of Medicine (NEJM) demonstrates that rituximab, a low-cost B-cell depleting therapy, is as effective as ocrelizumab in newly diagnosed relapsing multiple sclerosis (MS).

A $3 million gift from the Norman and Mary Pattiz Foundation will support promising research for Alzheimer’s disease at the Keck School of Medicine of USC, including novel drug discovery and other efforts aimed at early detection and prevention. The newly created Norman and Mary Pattiz Alzheimer’s Research Fund will provide pilot funding and accelerate priority projects of the USC Alzheimer’s Disease Research Center (ADRC). The gift will help fund an interdisciplinary team at the USC Center for Personalized Brain Health (CPBH) which is targeting a family of enzymes that can increase the risk of inflammation in the brains of people with the APOE4 gene variation—the most significant genetic risk factor for late-onset Alzheimer’s—as a way to prevent the disease. In addition to drug targeting which includes imaging modality development, and the use of artificial intelligence to pinpoint small molecules involved in brain inflammation, the fund will also support efforts to modernize the center’s brain pathology library and look at brain inflammation markers in patients with Alzheimer's. Also made possible by the funding will be a plan to create a registry for early detection of individuals at high risk for neuro-inflammation based on the APOE4 genetic variant and cardiovascular risk factors.